![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 29, Issue 11, 1410-1423, November 2001
Laboratory of Molecular Carcinogenesis and Laboratory of
Metabolism, National Cancer Institute, National Institutes of Health,
Bethesda, Maryland
Hybridomas were isolated that produce 13 monoclonal antibodies
(mAbs) that are specific and highly inhibitory to members of the human
P450 2C subfamily, 2C8, 2C9, 2C9*2, and 2C19. Many of the mAbs to P450
2C8, 2C9, and 2C19 are specific and exhibit potent inhibitory activity
(85-95%). mAb 281-1-1 specifically binds, immunoblots, and strongly
inhibits the activity of P450 2C8. mAb 763-15-5 specifically binds and
strongly inhibits the activity of P450 2C9. mAb 1-7-4-8 specifically
binds and strongly inhibits the activity of P450 2C19. The other mAbs
bind and inhibit sets and subsets of the P450 2C family. The single and
the combinatorial use of the mAbs can "reaction phenotype", i.e.,
determine the metabolic contribution and interindividual variation of a
P450 isoform for the metabolism of a drug or nondrug xenobiotic in human liver microsomes. The utility of the mAb-based analytic system
was examined with the model substrates Taxol (paclitaxel), diazepam,
tolbutamide, diclofenac, mephenytoin, and imipramine. The mAb system
can identify drugs metabolized by a common P450 or several P450s and
polymorphic P450s. The mAb system identifies drugs or drug metabolic
pathways that are catalyzed by a single P450 and thus may be used for
in vivo phenotyping. The mAb system can identify whether a particular
drug is metabolized by a single P450 that may exhibit polymorphic
expression in humans. The mAb system offers large potential for studies
of cytochrome P450 function useful in drug discovery and reduces the
possibility of adverse drug reactions due to polymorphisms and drug interactions.
This article has been cited by other articles:
|
|
 |
|
  M. Shou and A. Y. H. Lu Antibodies as a Probe in Cytochrome P450 Research Drug Metab. Dispos., May 1, 2009; 37(5): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Chang, W. Li, S. C. Traeger, B. Wang, D. Cui, H. Zhang, B. Wen, and A. D. Rodrigues Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro Drug Metab. Dispos., December 1, 2008; 36(12): 2513 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. L. Kiang, P. C. Ho, M. R. Anari, V. Tong, F. S. Abbott, and T. K. H. Chang Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype Toxicol. Sci., December 1, 2006; 94(2): 261 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Stuchal, K. M. Kleinow, J. J. Stegeman, and M. O. James DEMETHYLATION OF THE PESTICIDE METHOXYCHLOR IN LIVER AND INTESTINE FROM UNTREATED, METHOXYCHLOR-TREATED, AND 3-METHYLCHOLANTHRENE-TREATED CHANNEL CATFISH (ICTALURUS PUNCTATUS): EVIDENCE FOR ROLES OF CYP1 AND CYP3A FAMILY ISOZYMES Drug Metab. Dispos., June 1, 2006; 34(6): 932 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chang, D. E. Moody, and E. F. McCance-Katz NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE Drug Metab. Dispos., March 1, 2006; 34(3): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Gelboin and K. Krausz Monoclonal antibodies and multifunctional cytochrome p450: drug metabolism as paradigm. J. Clin. Pharmacol., March 1, 2006; 46(3): 353 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Quintieri, C. Geroni, M. Fantin, R. Battaglia, A. Rosato, W. Speed, P. Zanovello, and M. Floreani Formation and Antitumor Activity of PNU-159682, A Major Metabolite of Nemorubicin in Human Liver Microsomes Clin. Cancer Res., February 15, 2005; 11(4): 1608 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. N. Hirani, J. L. Raucy, and J. M. Lasker CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19 Drug Metab. Dispos., December 1, 2004; 32(12): 1462 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wang, R. I. Sanchez, R. B. Franklin, D. C. Evans, and S.-E. W. Huskey THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17{alpha}-ETHINYLESTRADIOL Drug Metab. Dispos., November 1, 2004; 32(11): 1209 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cai, R. W. Wang, R. W. Edom, D. C. Evans, M. Shou, A. D. Rodrigues, W. Liu, D. C. Dean, and T. A. Baillie VALIDATION OF (-)-N-3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., June 1, 2004; 32(6): 584 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hu, K. Krausz, J. Chen, X. Ge, J. Li, H. L. Gelboin, and Frank. J. Gonzalez IDENTIFICATION OF CYP1A2 AS THE MAIN ISOFORM FOR THE PHASE I HYDROXYLATED METABOLISM OF GENISTEIN AND A PRODRUG CONVERTING ENZYME OF METHYLATED ISOFLAVONES Drug Metab. Dispos., July 1, 2003; 31(7): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. H. Lu, R. W. Wang, and J. H. Lin Cytochrome P450 In Vitro Reaction Phenotyping: A Re-evaluation of Approaches Used for P450 Isoform Identification Drug Metab. Dispos., April 1, 2003; 31(4): 345 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Yu, J. R. Idle, K. W. Krausz, A. Kupfer, and F. J. Gonzalez Contribution of Individual Cytochrome P450 Isozymes to the O-Demethylation of the Psychotropic beta -Carboline Alkaloids Harmaline and Harmine J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 315 - 322. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
